Identification of an NAD(P)H: Quinone oxidoreductase polymorphism and its association with lung cancer and smoking

Pharmacogenetics

Volumn 5, Issue 4, 1995, Pages 199-206

  Rosvold, Elizabeth A ^a   McGlynn, Katherine A ^a   Lustbader, Edward D ^a   Buetow, Kenneth H ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

Lung cancer; NAD(P)H: Quinone oxidoreductase; NQ01 gene; Polymorphism; Smoking

Indexed keywords

CARCINOGEN; DNA; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE);

ALLELE; ARTICLE; BEHAVIOR; CHROMOSOME 16Q; CONTROLLED STUDY; EXON; GENE LOCUS; GENE MAPPING; GENE MUTATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MORBIDITY; PRIORITY JOURNAL; SMOKING;

ALLELES; BASE SEQUENCE; CASE-CONTROL STUDIES; CHROMOSOME MAPPING; CHROMOSOMES, HUMAN, PAIR 16; COMPARATIVE STUDY; DNA PRIMERS; EXONS; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMAN; LINKAGE (GENETICS); LUNG NEOPLASMS; MOLECULAR SEQUENCE DATA; NAD(P)H DEHYDROGENASE (QUINONE); POINT MUTATION; POLYMERASE CHAIN REACTION; POLYMORPHISM (GENETICS); POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; SMOKING; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0029073531     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-199508000-00003     Document Type: Article

References (39)

1. Ayesh R, Idle JR, Ritchie JC. Crothers MJ. Hetzel MR. Metabolic oxidation phenotypes as markers for susceptibility to lung cancer. Nature 1984: 312, 167-170.
2. Benìtez J, Ladero JM, Jara C, Carrillo JA, Cobaleda AL, Llerena A, Vargas E, Munoz JJ. Polymorphic oxidation of debrisoquine in lung cancer patients. Eur J Cancer 1991: 27, 158-161.
3. Brockmöller J, Kerb R, Drakoulis N, Nitz M, Roots I. Genotype and phenotype of glutathione-S-transferase class μ isoenzymes and μ, and ψ in lung cancer patients and controls. Cancer Res 1993: 53, 1004-1011.
4. Caporaso NE, Hayes RB, Dosemeci M, Hoover R, Ayesh R, Hetzel M, Idle J. Lung cancer risk, occupational exposure and the debrisoquine metabolic phenotype. Cancer Res 1989a: 49, 3675-3679.
5. Caporaso NE. Pickle LW, Bale S. Ayesh R. Hetzel M, Idle J. The distribution of debrisoquine metabolic phenotypes and implications for the suggested association with lung cancer risk. Genet Epidemiol 1989b: 6, 517-524.
6. Caporaso NE, Tucker MA, Hoover RN, Hayes RB, Pickle LW, Issaq HJ, Muschik GM, Green-Gallo L, Buivys D, Aisner S, Resau JH, Trump BF, Tollerud D, Weston A, Harris CC. Lung cancer and the debrisoquine metabolic phenotype. J Natl Cancer Inst 1990: 82, 1264-1272.
7. Caporaso N, Landi MT, Viners P. Relevance of metabolic polymorphisms to human carcinogenesis: evaluation of epidemiologie evidence. Pharmacogenetics 1991: 1, 4-19.
8. Caporaso N, Debaun MR, Rothman N. Lung cancer and CYP2D6 (the debrisoquine polymorphism): scores of heterogeneity in the proposed association. Pharmacogenetics 1995: 5, S129-S134.
9. Dausset J, Cann H, Cohen D, Lathrop M, Lalouel J, White R. Centre d'Etude du Polymorphisme Humain (CEPH): Collaborative Genetic Mapping of the Human Genome. Genomics 1990: 6, 575-577.
10. Duche JC, Joanne C, Barre J, de Cremoux H, Dalphin JC, Depierre A, Brochard P, Tillement JP, Bechtel P. Lack of a relationship between the polymorphism of debrisoquine oxidation and lung cancer. Br J Clin Pharmacol 1991: 31, 533-536.
11. Ernster L. DT-diaphorase. Methods Enzymol 1967: 10, 309-317.
12. Heckbert SR, Weiss NS, Hornung SK, Eaton DL, Motulsky AG. Glutathione S-transferase and epoxide hydrolase activity in human leukocytes in relation to risk of lung cancer and other smoking related cancers. J Natl Cancer Inst 1992: 84, 414-422.
13. Horsmans Y, Desager JP, Harvengt C. Is there a link between debrisoquine oxidation phenotype and lung cancer susceptibility? Biomed Pharmacother 1991: 45, 359-362.
14. Jaiswal AK. Human NAD(P)H: Quinone oxidoreductase (NQOl) gene structure and induction by dioxin. Biochemistry 1991: 30,10647-10653.
15. Jaiswal AK. McBride OW. Adesnik M. Nebert DW. Human dioxin-inducible cytosolic NAD(P)H:Menadione oxidoreductase. J Biolog Chem 1988: 263, 13572-13578.
16. Jaiswal AK. Jun and fos regulation of NAD(P)H: Quinone oxidoreductase gene expression. Pharmacogenetics 1994: 4, 1-10.
17. Kawajiri K, Watanabe J, Eguchi H, Hayashi S. Genetic polymorphisms of drug-metabolizing enzymes and lung cancer susceptibility. Pharmacogenetics 1995: 5, S70-S73.
18. Kärki NT, Pokela R, Nuutinen L, Pelkoren 0. Aryl hydrocarbon hydroxylase in lymphocytes and lung tissue from lung cancer patients and controls. Int J Cancer 1987: 39, 565-570.
19. Kellerman G, Shaw CR, Luyten-Kellerman M. Aryl hydrocarbon hydroxylase inducibility and bronchogenic carcinoma. New Eng J Med 1973: 289, 934-937.
20. Knudson AG. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 1971: 68, 820-823.
21. Knudson AG. Overview: genes that predispose to cancer. Mutat Res 1991: 247, 185-190.
22. Kouri RE, McKinney CE, Slomianry DJ, Snodgress DR, Wray NP, McLemore TL. Positive correlation between high aryl hydrocarbon hydroxylase activity and primary lung cancer as analyzed in cryopreserved lymphocytes. Cancer Res 1982: 42, 5030-5037.
23. Law MR, Hetzel MR, Idle JR. Debrisoquine metabolism and genetic predisposition to lung cancer. Br J Cancer 1989: 59, 686-687.
24. Lind C, Hochstein P, Ernster L. DT-diaphorase as a quinone reductase: a cellular control device against semiquinone and superoxide radical formation. Arch Biochem Biophys 1982: 216, 178-185.
25. Lind C. Cadenas E, Hochstein P, Ernster L. DT-Diaphorase: Purification, properties and function. Methods Enzymol 1990: 186,287-301.
26. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988: 16, 1215.
27. Morton NE. Sequential tests for the detection of linkage. Am J Hum Genet 1955: 7, 277-318.
28. Petruzzelli S, Camus AM, Carrozzi L, Ghelarducci L, Rindi M, Menconi G. Angeletti CA, Ahotupa M, Hietanen E, Aitio A, Saracci R, Bartsch H, Guintini C. Long-lasting effects of tobacco smoking on pulmonary drug metabolizing enzymes: A case-control study on lung cancer patients. Cancer Res 1988: 48, 4695-4700.
29. Roots I, Drakoulis N, Ploch M, Heinemeyer G, Loddenkemper R, Minks T, Nitz M, Otte F, Koch M. Debrisoquine hydroxylation phenotype, acetylation phenotype, and ABO blood groups as genetic host factors of lung cancer risk. Klin Wochenschr (suppl XI) 1988: 66, 87-97.
30. Schlager JJ, Powis G. Cytosolic NAD(P)H:(quinone-acceptor) oxidoreductase in human normal and tumor tissue: Effects of cigarette smoking and alcohol. Int J Cancer 1990: 45, 403-409.
31. Schor NA, Cornelisse CJ. Biochemical and quantitative histochem-ical study of reduced pyridine nucleotide dehydrogenation by human colonic carcinomas. Cancer Res 1983: 43, 4850-4855.
32. Seidegard J, Pero RW, Miller DG, Beattie EJ. A glutathione transferase in human leukocytes as a marker for the susceptibility to lung cancer. Carcinogenesis 1986: 7, 751-753.
33. Seidegard J, Pero RW, Markowitz MM, Roush G, Miller DG, Beattie EJ. Isoenzyme(s) of glutathione transferase (class Mu) as a marker for the susceptibility to lung cancer: a follow-up study. Carcinogenesis 1990: 11, 33-36.
34. Siegel D, Gibson NW, Preusch PC, Ross D. Metabolism of mitomycin C by DT-diaphorase: role in mitomycin C-induced DNA damage and cytotoxicity in human colon carcinoma cells. Cancer Res 1990: 50, 7483-7489.
35. Speirs CJ, Murray S, Davies DS, Biola Mabadeje AF, Boobis AR. Debrisoquine oxidation phenotype and susceptibility to lung cancer. Br J Clin Pharmacol 1990: 29, 101-109.
36. Talalay P, DeLong MJ, Prochaska HJ. Identification of a common chemical signal regulating the induction of enzymes that protect against chemical carcinogenesis. Proc Natl Acad Sci USA 1988: 85, 8261-8265.
37. Traver RD, Tetsuro H, Danenberg KD, Stadlbauer THW, Danenberg PV, Ross D, Gibson NW. NAD(P)H: Quinone oxidoreductase gene expression in human colon carcinoma cells: characterization of a mutation which modulates DT-diaphorase activity and mitomycin sensitivity. Cancer Res 1992: 52, 797-802.
38. Wolf CR, Smith CAD, Gough AC, Moss JE, Vallis KA, Howard G, Carey FJ, Mills K, McNee W, Carmichael J, Spurr NK. Relationship between the debrisoquine hydroxylase polymorphism and cancer susceptibility. Carcinogenesis 1992: 13, 1035-1038.
39. Zhong S, Howie AF, Ketterer B, Taylor J, Hayes JD, Beckett GJ, Wathen CG, Wolf CR, Spurr NK. Glutathione S-transferase mu locus: use of genotyping and phenotyping assays to assess association with lung cancer susceptibility. Carcinogenesis 1991: 12, 1533-1537.0.